Commentary: Resected pulmonary sarcomatoid carcinoma—a defined treatment paradigm, or just the end of the beginning of the search?

Batchelor, T.

doi:10.1016/j.jtcvs.2021.02.060

Cited by 1 publication

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For patients with PSC at an early stage, surgery is the best option (22,23). However, surgeons are seldom asked to make management decisions regarding PSC (24), and there is still debate about whether adjuvant chemotherapy can benefit patients with PSC.…”

Section: Discussionmentioning

confidence: 99%

An advanced pulmonary sarcomatoid carcinoma patient harboring a BRAFV600E mutation responds to dabrafenib and trametinib: a case report and literature review

2023

View full text Add to dashboard Cite

BackgroundThe pulmonary sarcomatoid carcinoma (PSC) is a rare and aggressive subtype of NSCLC with rapid progression and poor prognosis, and is resistant to conventional chemotherapy. Most PSC cases have potential targetable genomic alterations. Approximately 7% of PSC patients have BRAF mutations, and the efficacy of dabrafenib and trametinib in BRAFV600E mutated PSC is unclear.Case presentationOur report describes a patient with mutated BRAFV600E PSC who underwent surgery and adjuvant chemotherapy early but quickly relapsed. Both chemotherapy and immunotherapy were ineffective for him, combined dabrafenib and trametinib produced a 6-month progression-free survival, and a partial response was observed in the tumor response evaluation. As a result of financial pressure, he stopped taking the targeted drugs, and his disease rapidly progressed.ConclusionDabrafenib combined with trametinib provides partial remission in patients with advanced PSC with BRAFV600E mutations, and large-scale NGS panels could offer more options for PSC treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

An advanced pulmonary sarcomatoid carcinoma patient harboring a BRAFV600E mutation responds to dabrafenib and trametinib: a case report and literature review

2023

View full text Add to dashboard Cite

show abstract

Commentary: Resected pulmonary sarcomatoid carcinoma—a defined treatment paradigm, or just the end of the beginning of the search?

Abstract: Adjuvant chemotherapy should be offered to patients with resected stage II and III pulmonary sarcomatoid carcinoma, but the search for more targeted therapies continues.

Cited by 1 publication

References 5 publications

An advanced pulmonary sarcomatoid carcinoma patient harboring a BRAFV600E mutation responds to dabrafenib and trametinib: a case report and literature review

An advanced pulmonary sarcomatoid carcinoma patient harboring a BRAFV600E mutation responds to dabrafenib and trametinib: a case report and literature review

Contact Info

Product

Resources

About